Literature DB >> 17356388

The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.

Shereen Mohamed El-Maghraby1, Manar Mohamed Moneer, Manar Mohamed Ismail, Lobna M Shalaby, Hadir Ahmed El-Mahallawy.   

Abstract

BACKGROUND AND AIM: Recent advances in febrile neutropenia have highlighted the value of risk stratification especially that it can have important implications in terms of management. We aimed to identify a serum marker that may help to stratify febrile neutropenic pediatric patients treated for hematologic malignancies at the time of first evaluation. Thus, C-reactive protein (CRP), interleukin-8 (IL-8), and monocyte chemotactic protein-1-alpha (MCP-1-alpha) were evaluated for their predictive and diagnostic relevance in febrile episodes of cancer patients. PATIENTS AND METHODS: Within 24 hours of fever, CRP, IL-8, and MCP-1 serum levels were measured and the levels of these markers were related to the clinical findings of the patients. For this purpose, we collected and analyzed clinical data of 85 fever episodes occurring in 76 patients with hematologic malignancies, presenting to the Department of Pediatric Oncology, National Cancer Institute, Cairo University, during a 6-month period.
RESULTS: Neutropenic children with febrile episodes were classified into 2 groups, a group with unexplainable fever (group I, n=26) and another group with either blood culture positive, and/or fever periods with a documented clinical sepsis and/or local infection (group II, n=59). Clinically, local sites of infection were encountered in 39 cases (45.9%), whereas a positive blood culture was detected in 20 cases. CRP, IL-8, and MCP-1 levels were significantly lower in group I versus group II (P value <0.001). There were overlaps of values between groups. CRP > or =90 mg/L was significantly associated with chemotherapy-related neutropenia and fever owing to bacteremia (P=0.038). The sensitivity, specificity, negative and positive predictive values of CRP, MCP-1, and IL-8 were (70%, 73%, 51%, and 85%), (64%, 92%, 53%, and 95%), and (71%, 77%, 54%, and 88%), respectively. Combining 2 or 3 markers improved the diagnostic performance of these test, as 78% of group II had elevated 2 or 3 markers versus 16% of the group with no evident infection.
CONCLUSIONS: Low levels of CRP, MCP-1, and IL-8 could identify patients with unexplainable fever; whereas, high levels of these markers were of help in the diagnosis of infectious episodes. A model combining more than 1 marker is recommended in the assessment of febrile neutropenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356388     DOI: 10.1097/MPH.0b013e3180308770

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  14 in total

1.  Evaluation of predictors of adverse outcome in febrile neutropenic episodes in pediatric oncology patients.

Authors:  Meenakshi Bothra; Rachna Seth; Arti Kapil; S N Dwivedi; Shinjini Bhatnagar; Immaculata Xess
Journal:  Indian J Pediatr       Date:  2012-12-21       Impact factor: 1.967

Review 2.  Sepsis biomarkers: a review.

Authors:  Charalampos Pierrakos; Jean-Louis Vincent
Journal:  Crit Care       Date:  2010-02-09       Impact factor: 9.097

3.  Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding.

Authors:  Kendra N Iskander; Marcin F Osuchowski; Deborah J Stearns-Kurosawa; Shinichiro Kurosawa; David Stepien; Catherine Valentine; Daniel G Remick
Journal:  Physiol Rev       Date:  2013-07       Impact factor: 37.312

4.  Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia.

Authors:  Maria Hatzistilianou; Aleka Rekliti; Fanni Athanassiadou; Dorothea Catriu
Journal:  Inflamm Res       Date:  2009-10-06       Impact factor: 4.575

5.  Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis.

Authors:  Xin Huang; Yaping Chen; Chun-Shiang Chung; Zhenglong Yuan; Sean F Monaghan; Fei Wang; Alfred Ayala
Journal:  J Immunol       Date:  2013-12-30       Impact factor: 5.422

Review 6.  Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer.

Authors:  Robert S Phillips; Ros Wade; Thomas Lehrnbecher; Lesley A Stewart; Alex J Sutton
Journal:  BMC Med       Date:  2012-01-18       Impact factor: 8.775

7.  Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation-the protocol of the prospective cohort BIONEC study.

Authors:  Marco Bo Hansen; Ulf Simonsen; Peter Garred; Ole Hyldegaard
Journal:  BMJ Open       Date:  2015-05-11       Impact factor: 2.692

8.  Traditional chinese medicine diagnosis "yang-xu zheng": significant prognostic predictor for patients with severe sepsis and septic shock.

Authors:  Sunny Jui-Shan Lin; Yung-Yen Cheng; Chih-Hung Chang; Cheng-Hung Lee; Yi-Chia Huang; Yi-Chang Su
Journal:  Evid Based Complement Alternat Med       Date:  2013-10-24       Impact factor: 2.629

Review 9.  Biomarkers of sepsis: time for a reappraisal.

Authors:  Charalampos Pierrakos; Dimitrios Velissaris; Max Bisdorff; John C Marshall; Jean-Louis Vincent
Journal:  Crit Care       Date:  2020-06-05       Impact factor: 9.097

Review 10.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.